Obesity, Morbid clinical trials
The registry lists 941 studies for Obesity, Morbid across more than 10 countries. 163 are recruiting or about to start. 792 of them are mainly about Obesity, Morbid (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
ClinicalTrials.gov finds 1,102 studies for Obesity, Morbid. How that becomes 940 here
This page counts the studies the registry files under Obesity, Morbid, and those it files under no condition that list Obesity, Morbidthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 1,102Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −10List Obesity, Morbid as a condition, but the registry did not file them under itMost often written as “Morbid Obesity Requiring Bariatric Surgery” (5), “Clinically Severe Obesity” (4), and “Obesity, Morbid Catheterization, Peripheral” (1). The registry filed them under other conditions only, most often Obesity (7) and Gastroesophageal Reflux (2).
- −152Match it another way108 name it in the title, 1 in a keyword, and 43 by a synonym or other text the search reads.
- 940The count on this page7 of them list Obesity, Morbid in their own words; the registry filed them under no condition.
Get an email when these change. Save the Obesity, Morbid studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Norwegian University of Science and Technology (33) · Minia University (18) · Mansoura University (17) · Assistance Publique - Hôpitaux de Paris (13) · Rijnstate Hospital (11) · IHU Strasbourg (10) · Inonu University (9) · Hvidovre University Hospital (9)
What is being tested here
Drugs under test in Obesity, Morbid studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Semaglutide | 7 | 1 | 8 |
| Propofol | 1 | 1 | 6 |
| Mibavademab | 1 | 2 | 2 |
| Rivaroxaban | 1 | 0 | 2 |
| Tranexamic Acid | 1 | 1 | 2 |
| Mazdutide | 1 | 0 | 1 |
| GLP-1 Mimetic | 1 | 0 | 1 |
| Misoprostol | 1 | 0 | 1 |
| Desflurane | 1 | 0 | 1 |
| Naltrexone | 1 | 0 | 1 |
Drug classes tested here GLP-1 receptor agonists 7 open · Factor Xa inhibitors 1 open · Local anesthetics 8 · Opioids 7 · Stimulants 4
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Jun 2027A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults · Phase 3 · Regeneron Pharmaceuticals
- Nov 2026Iron Supplementation and Anemia After Sleeve Gastrectomy · Cairo University
- Nov 2026Stool Analysis After Sleeve Gastrectomy vs Gastric Bypass · Cairo University
- Nov 2026Videolaryngoscopes in the Morbidly Obese · Uniwersytet Radomski im. Kazimierza Pułaskiego
- Dec 2026Prevention of Coronary Heart Disease in Morbidly Obese Patients · The Hospital of Vestfold
- Dec 2026Bypass Equipoise Sleeve Trial (BEST) · Göteborg University
- Dec 2026Induction of Labor in Morbidly Obese Patients · University of Maryland, Baltimore
- Dec 2026Bariatric Surgery and Pharmacokinetics of Apixaban · Norwegian University of Science and Technology
- Dec 2026Bariatric Surgery and Pharmacokinetics of Ramipril · Norwegian University of Science and Technology
- Dec 2026Bariatric Surgery and Pharmacokinetics of Chlorprothixene · Norwegian University of Science and Technology
Who these studies take
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger. 8 (7%) take children under 18. 5 (5%) are for women only and 2 (2%) for men only; 9 (8%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 5 (5%) | 5 (5%) |
| 18 | 97 (89%) | 95 (87%) |
| 30 | 103 (94%) | 100 (92%) |
| 40 | 103 (94%) | 100 (92%) |
| 50 | 102 (94%) | 101 (93%) |
| 65 | 87 (80%) | 86 (79%) |
| 75 | 27 (25%) | 27 (25%) |
| 85 | 23 (21%) | 22 (20%) |
Across all 941 studies, recruiting or not: 71% stop at 75 or younger and 57% at 65; 9% take children; 6% are for women only and 1% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Obesity, Morbid studies take
Of 28 phase 4 interventional studies under Obesity, Morbid, half reached primary completion within 30 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 4 | 30 mo12–43 · 28 studies | — | — |
| Interventional, no phase | 25 mo11–48 · 286 studies | — | 25 mo11–48 · 274 studies |
| Observational | 46 mo16–132 · 138 studies | — | 46 mo16–132 · 137 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered6
- Improving Labor Management for Patients With Severe Obesity Using Abdominal Pannus RetractionNov 9, 2026NCT07924800
- Serum Estradiol and Endometrial Thickness After Bariatric Surgery in Postmenopausal Women With ObesityNov 5, 2026NCT07919054
- Closure Versus Non-Closure of Working Ports in Laparoscopic Sleeve GastrectomyNov 5, 2026NCT07919067
- Weight Loss and Comorbidity Outcomes After Revisional Bariatric SurgeryOct 19, 2026NCT07880691
- Glycemic Variability After SASI Versus Roux-en-Y Gastric BypassOct 13, 2026NCT07872397
Show 1 moreShow fewer
Studies
Recruiting first, then most recently updated. Showing 50 of 941. Browse all 941 → or search them.
- Exercise to Fight ObesityRecruitingNCT06934681Not applicable1 country
- Gut Microbiota in Metabolic SurgeryRecruitingNCT050009961 country
- Improving Labor Management for Patients With Severe Obesity Using Abdominal Pannus RetractionNot yet recruitingNCT07924800Not applicable1 country
- Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)Not yet recruitingNCT065471381 country
- Evaluating Metabolic Health in Individuals With Extreme ObesityNot yet recruitingNCT07613255
- Bariatric Surgery RegistryEnrolling by invitationNCT010550541 country
- Serum Estradiol and Endometrial Thickness After Bariatric Surgery in Postmenopausal Women With ObesityNot yet recruitingNCT079190541 country
- Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver DiseaseRecruitingNCT07058155Phase 41 country
- A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and AdultsRecruitingNCT07220772Phase 32 countries
- Impact GLP-1 Agonists Following BariatricRecruitingNCT06132477Phase 41 country
- Biometabolic Outcomes After Weight Loss Surgery: An Individualized ApproachEnrolling by invitationNCT04841057Not applicable1 country
- Bariatric Surgery and Pharmacokinetics of VenlafaxineRecruitingNCT035324771 country
- Glycemic Variability After SASI Versus Roux-en-Y Gastric BypassRecruitingNCT07872397Not applicable1 country
- Iron Supplementation and Anemia After Sleeve GastrectomyRecruitingNCT073975721 country
- Identification of Pre-surgical Phenotypic Indicators Predictive of Quality of Life Trajectories in Obese Patients Following Bariatric SurgeryRecruitingNCT06951893Not applicable1 country
- Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or HigherNot yet recruitingNCT07859137Phase 41 country
- Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)Not yet recruitingNCT07859150Phase 41 country
- Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric SurgeryNot yet recruitingNCT07859176Phase 41 country
- Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight GainNot yet recruitingNCT07859163Phase 41 country
- Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric SurgeryNot yet recruitingNCT07859189Phase 41 country
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruitingNCT004289871 country
- Continuous Glucose Monitoring in Metabolic SurgeryNot yet recruitingNCT07095972Not applicable1 country
- Prospective Study of an Explainable AI Tool to Support Biliopancreatic Limb Selection in One-Anastomosis Gastric BypassNot yet recruitingNCT078183171 country
- Comparison of Paragastric Nerve Block and Erector Spinae Plane Block on Postoperative Pain After Sleeve GastrectomyNot yet recruitingNCT07811206Not applicable
- TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric BypassRecruitingNCT07796503Not applicable1 country
- Postoperative Nausea, Vomiting and Pain After Bariatric Surgery - a National Registry StudyRecruitingNCT077973741 country
- Videolaryngoscopes in the Morbidly ObeseEnrolling by invitationNCT07787468Not applicable1 country
- Brown Adipose Tissue Activation by Spinal Cord StimulationRecruitingNCT04326192Not applicable1 country
- Early Discharge With Hospital-at-Home After Bariatric Surgery and Economic Evaluation.RecruitingNCT077822811 country
- Longitudinal Study of the Psychological Impact of Bariatric SurgeryRecruitingNCT077800581 country
- Bariatric Surgery and Pharmacokinetics of ParacetamolRecruitingNCT035384571 country
- Bariatric Surgery and Pharmacokinetics of LosartanRecruitingNCT035198931 country
- Bariatric Surgery and Pharmacokinetics of LamotrigineRecruitingNCT034971431 country
- Bariatric Surgery and Pharmacokinetics of ValsartanRecruitingNCT035353761 country
- Bariatric Surgery and Pharmacokinetics of MetoprololRecruitingNCT035199061 country
- Postextubation Use of Noninvasive Respiratory Support in Severely Obese PatientsRecruitingNCT05918575Not applicable2 countries
- Impact of MBS on Body Composition, Basal Metabolic Rates and Muscle Functions in Morbid Obese PatientsNot yet recruitingNCT07737860
- Induction of Labor in Morbidly Obese PatientsRecruitingNCT06199154Early Phase 11 country
- Investigating Metabolic, Brain, and Cognitive Alterations Through Bariatric SurgeryNot yet recruitingNCT077042291 country
- Bariatric Surgery and Pharmacokinetics of RamiprilRecruitingNCT034401771 country
- Bariatric Surgery and Pharmacokinetics of FluoxetineRecruitingNCT034765251 country
- Bariatric Surgery and Pharmacokinetics of EnalaprilRecruitingNCT034603661 country
- Bariatric Surgery and Pharmacokinetics of CandesartanRecruitingNCT034603271 country
- Bariatric Surgery and Pharmacokinetics of QuetiapineRecruitingNCT034494721 country
- Bariatric Surgery and Pharmacokinetics of ChlorprothixeneRecruitingNCT034494851 country
- Bariatric Surgery and Pharmacokinetics of HydrochlorothiazideRecruitingNCT034765511 country
- Bariatric Surgery and Pharmacokinetics of IbuprofenRecruitingNCT034765771 country
- Bariatric Surgery and Pharmacokinetics of ApixabanRecruitingNCT034487831 country
- Bariatric Surgery and Pharmacokinetics of LercanidipineRecruitingNCT034971561 country
- Bariatric Surgery and Pharmacokinetics of IrbesartanRecruitingNCT034766031 country